Drug intelligence / Profile preview

aspirin + dexchlorpheniramine + phenylephrine + caffeine

Development stage
Unknown
Lead developer
Brainfarma
Modality
Small Molecules
Administration
Oral
01

Overview

This drug is a fixed-dose combination of four active pharmaceutical ingredients: **aspirin**, **dexchlorpheniramine**, **phenylephrine**, and **caffeine**. Such combinations are formulated for the symptomatic relief of conditions like the common cold, flu, sinusitis, or allergic rhinitis where headache, nasal congestion, allergic symptoms, and fatigue coexist. **Aspirin** is a non-steroidal anti-inflammatory drug (NSAID) and analgesic that inhibits cyclooxygenases, resulting in reduced pain, fever, and inflammation. **Dexchlorpheniramine** is a first-generation antihistamine that acts as an H1 receptor antagonist, offering relief from allergic symptoms. **Phenylephrine** is a sympathomimetic amine acting as an alpha-1 adrenergic receptor agonist, serving as a decongestant by constricting blood vessels in the nasal mucosa. **Caffeine** is a central nervous system stimulant that can enhance pain relief when combined with analgesics and counteract drowsiness caused by antihistamines.

Brand names
Coristina D
Other names
Coristina d
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)mAChR (Muscarinic acetylcholine receptors)HRH1 (Histamine H1 Receptor)NET (Norepinephrine Transporter)ADOR (Adenosine receptors)ADRA1A (α1A)

Beyond the preview

Go deeper on aspirin + dexchlorpheniramine + phenylephrine + caffeine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + dexchlorpheniramine + phenylephrine + caffeine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call